Androgen Reduction Graph

Reimbursement Support

Reimbursement Codes and Allowables

Reimbursement Guide

Patient Education

Prostate Diseases

Patient Information from Package Insert

Androgen Reduction Graph

Physician Information


	Bayer Global
	Bayer Corporate - USA

	general conditions of use privacy statement imprint © 2007 Bayer HealthCare Pharmaceuticals

Physician Support
Androgen Reduction Graph

Androgen reduction success rate was 99 percent, as proven in clinical trials.^{1, 2, 3}


		Testosterone was below the castrate threshold between weeks 2 and 4 in 99 percent of patients, following the expected initial increase. As a result of this increase, prostate cancer-related symptoms may become worse during the first few weeks of treatment.
		Once reduced, testosterone remained well below the castrate threshold for the duration of the treatment.
		Reduction was maintained following removal and insertion of a new implant with no rise in testosterone.

Testosterone Reduction Graph³

Androgen Suppression Graph


	Printer-Friendly Version


	References


	Important Safety Considerations Viadur is contraindicated in patients with hypersensitivity to Gn-RH, Gn-RH agonist analogs, or any of the components in Viadur. Viadur is contraindicated in women and pediatric patients and was not studied in women or children. Viadur, like other LH-RH agonists, causes a transient increase in serum concentrations of testosterone during the first week of treatment. Patients may experience a worsening of symptoms or onset of new symptoms including bone pain, neuropathy, hematuria, or ureteral or bladder outlet obstruction, and spinal cord compression. The most comment systemic side effects were hot flashes (67.9%), asthenia (7.6%), gynecomastia (6.9%), depression (5.3%), and sweating (5.3%). The most common local side effects were bruising (34.6%) and burning (5.6%).
	Distributed and Marketed by:	Manufactured by:
	Bayer HealthCare Pharmaceuticals 6 West Belt, Wayne, NJ 07470 USA
	© Copyright 2007 Bayer HealthCare Pharmaceuticals. Viadur is a trademark of ALZA Corporation under license to Bayer HealthCare Pharmaceuticals. DUROS® is a registered trademark of ALZA Corporation. The information provided on Bayer products is only intended for the United States audience. Regulatory requirements, regulations, laws, and distribution of information about drug products may vary from country to country. Product names and indications (product uses) also may be different in different countries. The prescribing information provided here is based on United States labeling and may not be appropriate outside of the United States.